Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

NCT02156544 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia

Interventions

DRUG: CKD-519
DRUG: placebo

Sponsor

Chong Kun Dang Pharmaceutical